Trial · NCT04529005
Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
NCT04529005, Phase 4, Completed, University of Illinois Chicago; results first posted 2022-12-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients. Trials, record NCT04529005. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04529005
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Angiotensin II in the Perioperative Management of Hypotension in Kidney Transplant Recipients
- NCT number
- NCT04529005
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 20 participants, actual
- Lead sponsor
- University of Illinois Chicago
- Conditions
- Shock, Surgical, Shock, Hypotension and Shock, Kidney Transplant; Complications, Intraoperative Hypotension, Postoperative Hypotension
- Interventions
- Angiotensin II
- First posted
- 2020-08-27
- Last updated
- 2022-12-21
- Results first posted
- 2022-12-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duration of ATII Vasopressor Usage in the Intraoperative Setting | Duration of usage during the transplant surgery - presented in hours | Duration of vasopressor usage while in the operating room measured in hours of usage presented as median and IQR. |
| Secondary | Number (and Percentage) of Patients With Arrhythmias | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | The presence of arrhythmia was confirmed via EKG, flowsheet, or note documentation from the electronic medical record. |
| Secondary | Number (and Percentage) of Patients With Peripheral/Visceral Ischemia | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | The presence of digital or other peripheral/visceral ischemia was captured from reviewing chart documentation for each patient. |
| Secondary | Number (and Percentage) of Patients With Thrombosis | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging) |
| Secondary | Number (and Percentage) of Patients With Fungal Infections | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | The presence of post-operative fungal infections were captured prior to discharge as documented by the clinical care team in the electronic medical record. |
| Secondary | Number (and Percentage) of Patients With Hyperglycemia | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | The presence of hyperglycemia was captured for each patient and was determined by those patients requiring the use of an insulin infusion after their transplant surgery. |
| Secondary | Number (and Percentage) of Patients With Delayed Graft Function | From post-op to 7 days post-op | The presence of Delayed Graft Function was captured for each patient and defined by the need for renal replacement therapy up to 7 days post-operative. |
Source ClinicalTrials.gov
Outcomes7
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Duration of ATII Vasopressor Usage in the Intraoperative Setting | Duration of usage during the transplant surgery - presented in hours | Started ATII intraoperatively | hours | MEDIAN |
| SECONDARY | Number (and Percentage) of Patients With Arrhythmias | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number (and Percentage) of Patients With Peripheral/Visceral Ischemia | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number (and Percentage) of Patients With Thrombosis | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number (and Percentage) of Patients With Fungal Infections | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number (and Percentage) of Patients With Hyperglycemia | From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number (and Percentage) of Patients With Delayed Graft Function | From post-op to 7 days post-op | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group7
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of ATII Vasopressor Usage in the Intraoperative Setting | Angiotensin II (Giapreza) | 1 | Inter-Quartile Range 0.5 to 2 | hours | |
| Number (and Percentage) of Patients With Arrhythmias | Angiotensin II (Giapreza) | 1 | Participants | ||
| Number (and Percentage) of Patients With Peripheral/Visceral Ischemia | Angiotensin II (Giapreza) | 0 | Participants | ||
| Number (and Percentage) of Patients With Thrombosis | Angiotensin II (Giapreza) | 0 | Participants | ||
| Number (and Percentage) of Patients With Fungal Infections | Angiotensin II (Giapreza) | 0 | Participants | ||
| Number (and Percentage) of Patients With Hyperglycemia | Angiotensin II (Giapreza) | 1 | Participants | ||
| Number (and Percentage) of Patients With Delayed Graft Function | Angiotensin II (Giapreza) | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Angiotensin II (Giapreza) | 20 | |
| Overall Study | COMPLETED | Angiotensin II (Giapreza) | 20 | |
| Overall Study | NOT COMPLETED | Angiotensin II (Giapreza) | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Angiotensin II (Giapreza) | 1 | 20 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Angiotensin II (Giapreza) | 0 | 20 |
| Total, other adverse events | Angiotensin II (Giapreza) | 1 | 20 |
| Total, serious adverse events | Angiotensin II (Giapreza) | 0 | 20 |
Source ClinicalTrials.gov
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04529005
GET https://conductscience.org/api/trials/v1/NCT04529005/registered